1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 Mar 2024
Admin
News Article

Taletrectinib Gets Second NDA for ROS1-Positive Lung Cancer

AnHeart Therapeutics and Innovent Announce China's NMPA Acceptance of Second New Drug Application for Taletrectinib in First-Line Treatment of ROS1-Positive Lung Cancer

Overview

AnHeart Therapeutics, a global biopharmaceutical company specializing in precision cancer therapies, and Innovent Biologics, Inc., a leading biopharmaceutical firm focusing on oncology and other major diseases, have jointly announced that the National Medical Products Administration (NMPA) of China has accepted a second New Drug Application (NDA) for taletrectinib. Taletrectinib is a next-generation ROS1 tyrosine kinase inhibitor (TKI) intended for use as a first-line treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have not previously undergone treatment with ROS1 TKIs.

Previous NDA

Previously, in 2023, the NMPA accepted the first NDA for taletrectinib, granting Priority Review Designation for adult patients with locally advanced or metastatic ROS1-positive NSCLC who had received prior treatment with ROS1 TKIs.
These NDAs are based on positive results from the Phase 2 TRUST-I trial (NCT04395677), with interim analysis data presented at the European Lung Cancer Congress (ELCC) 2023 and additional data planned for presentation at a forthcoming medical meeting in 2024.

Words from Principal Investigator

Professor Caicun Zhou, Principal Investigator and Oncologist at Shanghai Pulmonary Hospital, welcomed the acceptance of the second NDA for taletrectinib, emphasizing the importance of additional treatment options for newly diagnosed patients with advanced or metastatic ROS1-positive NSCLC.

Words from AnHeart China

Bing Yan, MD, President of AnHeart China, underscored the potential of taletrectinib as a first-line treatment and the company's dedication to advancing transformative therapies for cancer patients in partnership with Innovent.

Innovent Leadership on NDA Acceptance

Dr. Hui Zhou, Senior Vice President of Innovent, expressed optimism about taletrectinib's clinical benefits and its acceptance by the NMPA, highlighting the goal of making this targeted therapy available to all eligible patients with ROS1-positive NSCLC as an initial treatment choice.

About Taletrectinib

Taletrectinib, an oral, potent, brain-penetrant, selective next-generation ROS1 inhibitor, is currently undergoing evaluation in two Phase 2 trials: TRUST-I in China (NCT04395677) and TRUST-II (NCT04919811), a global pivotal trial.
In 2022, taletrectinib received Breakthrough Therapy Designation from the NMPA for the treatment of advanced or metastatic ROS1-positive NSCLC in both TKI-naïve patients and those previously treated with ROS1 TKIs.
It also obtained Breakthrough Therapy Designation in the United States for the same indication from the FDA.

Motto Behind Agreement

AnHeart and Innovent entered into an exclusive license agreement in 2021 for the co-development and commercialization of taletrectinib in Greater China, including mainland China, Hong Kong, Macau, and Taiwan.

ROS1-Positive NSCLC

In China, approximately 3% of NSCLC patients are ROS1-positive. While there are approved first-generation TKIs for newly diagnosed patients, there are no approved therapies for those whose cancer has progressed after initial treatment.
Moreover, a significant proportion of patients with metastatic ROS1-positive NSCLC develop brain metastases, emphasizing the urgent need for effective treatments in this population.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!